p53 status of newly established acute myeloid leukaemia cell lines

被引:24
|
作者
Zheng, A
Castren, K
Säily, M
Savolainen, ER
Koistinen, P
Vähäkangas, K
机构
[1] Oulu Univ, Dept Clin Chem, FIN-90220 Oulu, Finland
[2] Oulu Univ, Dept Internal Med, FIN-90220 Oulu, Finland
[3] Oulu Univ, Dept Pharmacol & Toxicol, FIN-90220 Oulu, Finland
关键词
p53; AML; cell lines;
D O I
10.1038/sj.bjc.6690064
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
We analysed the status of the p53 gene and protein in eight newly established acute myeloid leukaemia (AML) cell lines representing blast cells of either de novo leukaemia patients in first remission or patients with relapsed and chemotherapy-resistant disease causing their death. There were no mutations in the p53 gene in any of the cell lines as analysed by single-strand conformation polymorphism of amplified exons 5-8. However, the p53 protein was clearly and consistently expressed in all of these cell lines, as shown by immunohistochemistry, Western blotting and flow cytometry. The consistently expressed p53 protein was located in both the nucleus and the cytoplasm of all the cell lines and, as shown by flow cytometry, it was mostly in a conformation typical of the mutated protein. These AML cell lines offer a tool for studying the production and function of the p53 protein and its possible role in cell cycle regulation and chemoresistance as well as in the regulation of apoptosis in AML.
引用
收藏
页码:407 / 415
页数:9
相关论文
共 50 条
  • [1] p53 status of newly established acute myeloid leukaemia cell lines
    A Zheng
    K Castren
    M Säily
    E-R Savolainen
    P Koistinen
    K Vähäkangas
    British Journal of Cancer, 1999, 79 : 407 - 415
  • [2] Correlation of p53 immunohistochemistry with TP53 mutational status and overall survival in newly diagnosed acute myeloid leukaemia
    Fitzpatrick, Megan J.
    Boiocchi, Leonardo
    Fathi, Amir T.
    Brunner, Andrew M.
    Hasserjian, Robert P.
    Nardi, Valentina
    HISTOPATHOLOGY, 2022, 81 (04) : 496 - 510
  • [3] Role of P53 deletion in patients with acute myeloid leukaemia
    Ismail, Mona A.
    Ahmed, Tamer M.
    Ahmed, Iman Z.
    EGYPTIAN JOURNAL OF HAEMATOLOGY, 2012, 37 (04): : 252 - 256
  • [4] P53 IN CHRONIC MYELOID-LEUKEMIA CELL-LINES
    BI, SC
    HUGHES, T
    BUNGEY, J
    CHASE, A
    DEFABRITIIS, P
    GOLDMAN, JM
    LEUKEMIA, 1992, 6 (08) : 839 - 842
  • [5] MDM2 AND P53 CODON 72 POLYMORPHISMS IN ACUTE MYELOID LEUKAEMIA
    El-Danasouri, N. M.
    Ragab, S. H.
    Rasheed, M. A.
    El-Sadaany, Z. A.
    Abd El-Fattah, S. N.
    EUROPEAN JOURNAL OF CANCER, 2014, 50 : E38 - E38
  • [6] Mutational inactivation of p53 tumor suppressor gene in two newly established human prostate cancer cell lines.
    Ozen, M
    Mukhopadhyay, T
    Radinsky, R
    Chung, LWK
    Pathak, S
    AMERICAN JOURNAL OF HUMAN GENETICS, 1997, 61 (04) : A76 - A76
  • [7] Telomeric length in individuals and cell lines with altered p53 status
    Kruk, PA
    Bohr, VA
    RADIATION ONCOLOGY INVESTIGATIONS, 1999, 7 (01): : 13 - 21
  • [8] Impact of p53 and BCL2 Expression on Prognosis in Patients with Acute Myeloid Leukaemia
    McDonald, Laura
    Hennessy, Brian
    Kumar, Senthil
    Nur, Mutaz
    Schilling, Christine
    El Hassadi, Ezzat
    BLOOD, 2020, 136
  • [9] Gene transfer to primary acute myeloid leukaemia blasts and myeloid leukaemia cell lines
    Roddie, PH
    Paterson, T
    Turner, ML
    CYTOKINES CELLULAR & MOLECULAR THERAPY, 2000, 6 (03) : 127 - 134
  • [10] Hydroxyurea synergizes with valproic acid in wild-type p53 acute myeloid leukaemia
    Leitch, Calum
    Osdal, Tereza
    Andresen, Vibeke
    Molland, Maren
    Kristiansen, Silje
    Xuan Nhi Nguyen
    Bruserud, Oystein
    Gjertsen, Bjorn Tore
    McCormack, Emmet
    ONCOTARGET, 2016, 7 (07) : 8105 - 8118